<DOC>
	<DOCNO>NCT00154713</DOCNO>
	<brief_summary>The specific aim study follow : 1 . Primary endpoint : evaluate clinical response vaccinate patient . 2 . Secondary endpoint : evaluate safety treatment immune response CEA treatment</brief_summary>
	<brief_title>Immunotherapy Colorectal Cancers Using CEA-Pulsed Dendritic Cells Subsequent IL-2 Treatment</brief_title>
	<detailed_description>In trial , immunize metastatic colorectal cancer patient recombinant CEA-pulsed DCs mixed tetanus toxoid subcutaneous injection . Low dose IL-2 give subcutaneously follow DC vaccination boost growth T cell . We adapt “ Simon ’ optimal two-stage design ” study . In first stage , treat 12 patient evaluate safety new protocol . If severe toxicities/side effect least one patient stable disease well clinical response , proceed second stage treat additional 25 patient . We follow clinical outcome 37 patient . The immune response CEA vaccination examine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients must metastatic colorectal cancer . Patients must least one measurable lesion . Patients ’ serum level CEA must higher 5 time normal value Patients ’ disease must fail chemotherapy 5FU , CPT11 oxaliplatin . Patients unsuitable refuse chemotherapy consider eligible trial . Patients ’ age must 20 great . Patients ’ estimate life expectancy 3 month . Patients must adequate bone marrow function , define WBC &gt; = 3500/mm3 , neutrophil &gt; = 1500/mm3 , lymphocyte &gt; = 1,000/mm3 , platelet &gt; = 100,000/mm3 . Patients must adequate liver renal function , define serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) = &lt; 5 time normal , bilirubin = &lt; 1.5 time normal range , creatinine = &lt; 2 time upper normal limit . All patient documentation negative result penicillin test . Women men reproductive potential may participate unless agree use effective contraceptive method . All patient must inform investigational nature study must sign give write informed consent . Patients central nervous system metastasis except whose CNS disease treat radiotherapy and/or surgery stable least two week Patients active acute chronic infection ( discretion investigator ) . Pregnant breastnursing woman Patients active cardiac disease require therapy failure , angina , arrythmia , infarction within precede 6 month ( exception : patient whose cardiac failure compensate medication ) Patients asthma Patients autoimmune disease inflammatory bowel disease , lupus erythematosus , ankylose spondylitis , scleroderma , multiple sclerosis Patients serious concomitant systemic disorder incompatible study ( discretion investigator ) Patients prior concurrent malignancy except insitucarcinoma cervix adequately treat basal cell carcinoma skin . Patients receive chemotherapy , steroid biologic treatment within 4 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>CEA</keyword>
	<keyword>IL-2</keyword>
</DOC>